Cormorant Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

Cormorant Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.9M	Sell	2,150,000 -1,750,000	-45%	-$23.4M	1.38%	22
2026 Q1	$58.1M	Buy	3,900,000 +1,150,000	+42%	+$25.6M	2.92%	13
2025 Q4	$68.8M	Buy	+2,750,000	New	+$48.9M	3.18%	12
2024 Q1	–	Sell	-2,456,800	Closed	-$34.5M	–	61
2023 Q4	$34.5M	Sell	2,456,800 -2,047,964	-45%	-$27.5M	1.65%	19
2023 Q3	$55.6M	Buy	4,504,764 +1,422,764	+46%	+$14.5M	3.25%	7
2023 Q2	$27.8M	Hold	3,082,000	–	–	1.56%	18
2023 Q1	$10.7M	Buy	3,082,000 +1,000,000	+48%	+$4.08M	0.7%	36
2022 Q4	$5.1M	Hold	2,082,000	–	–	0.34%	57
2022 Q3	$5.75M	Hold	2,082,000	–	–	0.4%	51
2022 Q2	$8.47M	Hold	2,082,000	–	–	0.64%	43
2022 Q1	$8.87M	Sell	2,082,000 -87,871	-4%	-$484K	0.68%	44
2021 Q4	$20.3M	Sell	2,169,871 -903,614	-29%	-$18.7M	1.21%	25
2021 Q3	$84.7M	Hold	3,073,485	–	–	3.44%	6
2021 Q2	$86M	Sell	3,073,485 -122,059	-4%	-$3.47M	2.92%	8
2021 Q1	$105M	Hold	3,195,544	–	–	2.34%	11
2020 Q4	$148M	Buy	+3,195,544	New	+$150M	3.53%	8

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Cormorant Asset Management's OLMA Position: Q2 2026 in Review

Cormorant Asset Management reduced its Olema Pharmaceuticals (OLMA) stake by 45% in Q2 2026, selling an estimated $23.4M and leaving 2,150,000 shares worth $26.9M. The position accounts for 1.38% of the portfolio, ranked #22.

Cormorant Asset Management first reported a position in OLMA in Q4 2020 and has held it in 16 quarters since. The position peaked at $148M in Q4 2020. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

Cormorant Asset Management held 2,150,000 shares of Olema Pharmaceuticals worth $26.9M as of Q2 2026.
Cormorant Asset Management sold 1,750,000 Olema Pharmaceuticals shares in Q2 2026, an estimated $23.4M.
Olema Pharmaceuticals made up 1.38% of Cormorant Asset Management's portfolio in Q2 2026, its #22 holding.
Cormorant Asset Management first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
Cormorant Asset Management's Olema Pharmaceuticals position peaked at $148M in Q4 2020.
185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.